Transcenta Holding Limited (6628.HK) announced it has entered into a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc., a global biopharmaceutical development and manufacturing company.
Under the agreement, Transcenta will grant EirGenix a non-exclusive license to use its Highly Intensified Continuous Bioprocessing (HiCB) platform. This includes highly productive continuous perfusion and integrated hybrid continuous purification process technologies, supported by comprehensive process documentation, know-how, and regulatory packages. Transcenta will receive substantial upfront and milestone payments, along with future royalties tied to the commercial use of the licensed technologies.
The HiCB platform is designed to enhance process efficiency, improve control and product consistency, and significantly reduce manufacturing costs compared to conventional fed-batch processes. The improvements aim to expand global patient access to high-quality, affordable biologics.
Through this collaboration, EirGenix will adopt Transcenta's HiCB platform to advance its biologics development programs and manufacturing operations. The company also plans to apply the platform to serve CDMO clients seeking intensified and continuous manufacturing solutions.
For comments and feedback contact: editorial@rttnews.com
Business News
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.